

Cranial TCP/NTCP Modeling Insights and Caveats

Issam El Naqa, MA, PhD

The Department of Radiation Oncology University of Michigan



Jimm Grimm and Ellen Yorke Andy Jackson, Randy Ten Haken and the WGSBRT

Cranial TCP team

- Scott G. Soltys, MD
- Jinyu Xue, PhD
- Michael T. Milano, MD, PhD
- Wolfgang A. Tomé, PhD
- Andrew Jackson, PhD
- George Ding, PhD
- Arjun Sahgal, MD
- Lijun Ma, PhD
- Timothy Solberg, PhD
- John P. Kirkpatrick, MD PhD
- Lawrence B. Marks, MD
- John Adler, MD
- Radiation Oncology JP Sheehan , MD

Cranial NTCP team

- Michael T. Milano, MD, PhD
- Wolfgang A. Tomé, PhD
- Vitali Moiseenko, PhD
- Jinyu Xue, PhD
- Arjun Sahgal, MD
- Lijun Ma, PhD
- Scott G. Soltys, MD
- Timothy Solberg, PhD
- John P. Kirkpatrick, MD PhD
- Lawrence B. Marks, MD
- John C. Flickinger, MD



• Definition:

- The use of mathematics, physics and computer science to study the behavior of complex systems by computer simulation
- Objective:

 To make predictions about what will happen in the real system that is being studied in response to changing conditions




• Definition:

 The use of mathematics, physics, biology, and computer science to study the behavior of tissue response to irradiation by computer simulation

• Objective:


 To make predictions about what will happen in the patient that is being treated in response to changing irradiation conditions






Adapted from Berry & Linoff, 2004








University of Michigan Medical School




07/16/2015 7

University of Michigan Medical School Linear-quadratic (LQ) model



Douglas & Fow167,01972

Biological effective dose (BED)



$$BED = (nd) \left(1 + \frac{d}{(\alpha / \beta)} \right)$$



The BED for a treatment of 60 Gy in 30 fractions for an organ that has $\alpha/\beta=2$ Gy is:

10%	1.	30 Gy
36%	2.	60 Gy
37%	3.	90 Gy
16%	4.	120 Gy
<mark>1</mark> %	5.	150 Gy

Radiation Oncology



The BED for a treatment of 60 Gy in 30 fractions for an organ that has $\alpha/\beta=2$ Gy is:

- 1. 30 Gy
- 2. 60 Gy
- 3. 90 Gy
- 4. 120 Gy
- 5. 150 Gy

<u>Reference:</u> Fowler JF. 21 years of biologically effective dose. Br J Radiol. 2010 Jul;83(991):554-68.



Schedule type Total dose BED (**Gy**) Gy_{10} (early Gy₃ (late) effect, tumor) 30 fx 2 Gy / 6 wks100 60 72 70f x 1.15 Gy BID/ 80.5 111.4 89.8 7 wks 35f x 2 Gy/7 wks 70 84 116.7 ([30f x 1.8 Gy] +72 113.4 84.4 [12f x1.5 Gy])/6 wks 3f x 20 Gy 60 180 460

ICRU Bioeffect Modelling and Equieffective Dose Concepts in Radiation Therapy

<u>Definition</u>: Two radiation treatment regimens having different dose-timefractionation schedules or dose rate patterns, and/or different spatial distributions and/or different radiation qualities are said to be *equieffective* with respect to a specific clinical (biological) endpoint, if they produce the same probability of reaching this endpoint when delivered under the carefully specified conditions.

$$\mathrm{EQD}X_{lpha/eta} = D \cdot rac{d+lpha/eta}{X+lpha/eta}$$
 g

The total absorbed dose delivered by the reference treatment plan (fraction size X) that leads to the same biological effect as a test treatment plan that is conducted with absorbed dose per fraction d and total absorbed dose D expressed in units of Gy.



The correct ICRU recommendation for equieffective dose nomenclature of equivalent 2 Gy per fraction with an α/β =10 Gy is:






The correct ICRU recommendation for equieffective dose nomenclature of equivalent 2 Gy per fraction with an $\alpha/\beta=10$ Gy is

- 1. EQD2 Gy₁₀
- 2. EQD10 Gy₂
- 3. EQD2₁₀ Gy
- 4. EQD10₂ Gy
- 5. None of the above.

Reference: Bentzen SM, Dörr W, Gahbauer R, Howell RW, Joiner MC, Jones B, Jones DT, van der Kogel AJ, Wambersie A, Whitmore G. Bioeffect modeling and equieffective dose concepts in radiation oncology--terminology, quantities and units. Radiother Oncol. 2012 Nov;105(2):266-8.



- <u>Tumor control probability</u> (<u>TCP):</u> The probability of local control given the planned dose distribution.
- <u>Normal Tissue</u>
 <u>Complication Probability</u>
 <u>(NTCP)</u>: The probability of some defined undesirable effect on the patient due to the irradiation.



Courtesy Joseph Deasy

Holthusen (1/936)16



Modified LQ (MLQ) or Lq-Linear (LQL) (Guerrero, 2004):

 $SF = \exp(-\partial D - bG(\partial D)D^{2})$ $G = \frac{2}{(\partial D)^{2}} \left(\exp(-\partial D) + \partial D - 1\right)$

• LQ cubic (LQC) (Joiner and Kogel, 2009):


$$SF = \exp(-\alpha D - \beta D^2 + \gamma D^3)$$

• Universal survival curve (USC) (Park, 2008):

$$\ln SF = \begin{cases} -n(\alpha d + \beta G d^2), d \le D_T \\ -n(\frac{d}{D_0} - \frac{D_q}{D_0}), d \ge D_T \end{cases}$$




The Universal Survival Curve



Radiation Oncology Park et al., IJROBP, 2008

SBRT Survival curves






Radiation Oncology Park et al., RR, 2012




- Estimation of alpha/beta ratio
 - Fe-plot
 - dD-D plot
- Modeling of TCP
 - Biological dose correction (LQ, LQL, LQC, EQD2)
 - Model form: Poisson






Radiation Oncology






Radiation Oncology

Observational point effect University of Michigan





 γ_{50} =0.1908 (0.167,0.214)

EQD2 (Gy)

0.2


0.1

Radiation On




- Actuarial analysis (Kaplan Meier)
- Modeling of NTCP
 - Biological dose correction (BED, EQD2, conversion to different fractions)
 - Model form: Probit


NTCP model (alpha/beta=1.6) University of Michigan Medical School



NTCP model (alpha/beta=1.6) University of Michigan Medical School




NTCP model (alpha/beta=1.6) University of Michigan Medical School





Modeling is a marriage between Mr. Data and Miss Model






GIGO paradigm

TWEEDIE, R.L., MENGERSEN, K.L., ECCLESTON, J.A. (1994)
 Garbage in, garbage out: can statisticians quantify the effects of poor data? Chance 7, 20-27.





There are models and there are 'super'-models



Radiation Oncology



Jimm Grimm and Ellen Yorke Andy Jackson, Randy Ten Haken and the WGSBRT

Cranial TCP team

- Scott G. Soltys, MD
- Jinyu Xue, PhD
- Michael T. Milano, MD, PhD
- Wolfgang A. Tomé, PhD
- Andrew Jackson, PhD
- George Ding, PhD
- Arjun Sahgal, MD
- Lijun Ma, PhD
- Timothy Solberg, PhD
- John P. Kirkpatrick, MD PhD
- Lawrence B. Marks, MD
- John Adler, MD
- Radiation Oncology JP Sheehan , MD

Cranial NTCP team

- Michael T. Milano, MD, PhD
- Wolfgang A. Tomé, PhD
- Vitali Moiseenko, PhD
- Jinyu Xue, PhD
- Arjun Sahgal, MD
- Lijun Ma, PhD
- Scott G. Soltys, MD
- Timothy Solberg, PhD
- John P. Kirkpatrick, MD PhD
- Lawrence B. Marks, MD
- John C. Flickinger, MD